Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
KALA BIO, Inc. - Common Stock
(NQ:
KALA
)
0.1851
-0.0149 (-7.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about KALA BIO, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
AI Pharma Startup METiS Raises $150 Million. IPO In Sight?
↗
April 12, 2022
Key takeaways: METiS Pharmaceuticals has completed five funding rounds since its establishment in January 2020, including the latest two worth $150 million The company was...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2022
↗
March 30, 2022
Upgrades
Via
Benzinga
Recap: Kala Pharmaceuticals Q4 Earnings
↗
March 29, 2022
Kala Pharmaceuticals (NASDAQ:KALA) reported its Q4 earnings results on Tuesday, March 29, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For May 16, 2022
↗
May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Via
Benzinga
Earnings Preview For Kala Pharmaceuticals
↗
May 13, 2022
Kala Pharmaceuticals (NASDAQ:KALA) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Kala...
Via
Benzinga
66 Biggest Movers From Yesterday
↗
May 03, 2022
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...
Via
Benzinga
Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases
↗
May 02, 2022
Via
Benzinga
53 Biggest Movers From Yesterday
↗
March 30, 2022
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
March 29, 2022
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $8.5 million.
Via
Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
↗
March 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For March 29, 2022
↗
March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.
Via
Benzinga
Earnings Outlook For Kala Pharmaceuticals
↗
March 28, 2022
Kala Pharmaceuticals (NASDAQ:KALA) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Kala...
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
↗
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
How To Attend Kala Pharmaceuticals Q4 2021 Earnings Conference Call
↗
March 24, 2022
Kala Pharmaceuticals (NASDAQ:KALA) will host a conference call at 08:00 AM ET on March 29, 2022, to discuss Q4 2021 earnings results. How to Attend Kala Pharmaceuticals (KALA)...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
March 23, 2022
Gainers Creative Medical Tech (NASDAQ:CELZ) shares rose 78.8% to $3.04 during Wednesday's pre-market session. The market value of their outstanding shares is at $19.2...
Via
Benzinga
95 Biggest Movers From Friday
↗
March 14, 2022
Gainers Marygold Companies (NYSE: MGLD) shares surged 89.4% to close at $4.11 on Friday after dropping 21% on Thursday. TeraWulf Inc. (NASDAQ: WULF) gained 49.3% to close at $9....
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
↗
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
March 11, 2022
Gainers CVRx (NASDAQ:CVRX) shares rose 11.6% to $7.2 during Friday's after-market session. The market value of their outstanding shares is at $156.2 million.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
March 11, 2022
Gainers Clearside Biomedical (NASDAQ:CLSD) shares increased by 35.2% to $1.82 during Friday's regular session. Clearside Biomedical's stock is trading at a volume...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
March 10, 2022
Gainers Salarius Pharmaceuticals (NASDAQ:SLRX) stock moved upwards by 31.4% to $0.49 during Thursday's regular session. The current volume of 2.4 million shares is 738...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
March 09, 2022
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock rose 222.4% to $4.9 during Wednesday's pre-market session. The company's market cap stands at $21.9 million. TC...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
March 08, 2022
Gainers
Via
Benzinga
88 Biggest Movers From Yesterday
↗
March 09, 2022
Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC) climbed 203.3% to settle at $1.00 on Tuesday. Hycroft recently reported preliminary FY21 operating results. Kala...
Via
Benzinga
This Microcap Pharma Stock Almost Doubled Today - Read Why
↗
March 08, 2022
UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ: KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its ...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
March 08, 2022
Gainers Kala Pharmaceuticals (NASDAQ:KALA) stock rose 86.8% to $1.14 during Tuesday's regular session. The current volume of 2.6 million shares is 326.2% of Kala...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
February 28, 2022
Gainers GBS (NASDAQ:GBS) stock rose 10.9% ...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
February 23, 2022
Gainers Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
December 21, 2021
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock moved upwards by 75.98% to $4.47 during Tuesday's pre-market session. The company's market cap stands at $62.8...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
November 19, 2021
Gainers CASI Pharmaceuticals (NASDAQ:CASI
Via
Benzinga
Kala Pharma Acquires Ocular Surface Disease-Focused Company
↗
November 15, 2021
Kala Pharmaceuticals Inc (NASDAQ: KALA) has acquired Combangio Inc, a private company developing regenerative biotherapies for severe ocular surface diseases....
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.